Merck Investor Sues Over Gardasil China Market Projections

By Sydney Price · February 13, 2025, 5:57 PM EST

Pharmaceutical giant Merck & Co. Inc. has been hit with a proposed shareholder class action alleging it overstated global demand for its human papillomavirus vaccine Gardasil, damaging investors when it revealed...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

CRONIN v. MERCK & CO. et al

Case Number

Court

New Jersey

Nature of Suit

Securities/Commodities

Date Filed

February 12, 2025

Recent Articles By Sydney

February 10, 2025
Pharma Co. Misled Investors On Depression Drug, Suit Says
January 22, 2025
Pharma Co. Says Ex-CEO's Alleged Misconduct Is Not Fraud
January 08, 2025
Biotech Co.'s Facility Failures Lost Investors Money, Suit Says
January 02, 2025
Edwards Brass Face Investor Suit Over Heart Valve Sales
December 02, 2024
Investor Alleges Medical Device Co. Misled On FDA Clearance
November 21, 2024
SEC Denied Civil Penalties Over Pot Pill Exec's 'Inexperience'
November 15, 2024
Healthcare Co. PACS Made False Claims Before IPO, Suit Says
November 13, 2024
Biotech Brass Misled Investors About Cancer Drugs, Suit Says
October 29, 2024
Y-mAbs Therapeutics Investors Get Final OK For $19.7M Deal
October 29, 2024
Biopharma Co. Escapes Investor Suit Over Drug Approval Lies